NASDAQ:CNSP

Cns Pharmaceuticals Stock Insider Trading

etoro logo Buy CNSP
*Your capital is at risk
$5.24
+0.320 (+6.50%)
At Close: Jun 03, 2026

CNS Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 3.68M and sold 0 CNSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 3.68M shares
Sell 0 shares
100% Buy Activity
Negligible or No Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
May 18, 2026
Buy
Common Stock
P-Purchase
Charles Faith L.
Director
Director 7 100
Value: $34.0K
Mar 02, 2026
Buy
Common Stock
J-Other
O'loughlin Steve
Officer
Officer 0
Value: $0
Mar 02, 2026
Buy
Restricted Stock Units
A-Award
O'loughlin Steve
Chief Financial Officer
C-Suite Officer 9 500
Value: $29.7K
Mar 02, 2026
Buy
Common Stock
J-Other
Faulkner Eric
Officer
Officer 0
Value: $0
Mar 02, 2026
Buy
Restricted Stock Units
A-Award
Faulkner Eric
Chief Technology Officer
Officer 9 500
Value: $29.7K
Jan 01, 2026
Buy
Common Stock
J-Other
Levin Rami
CEO And President
CEO / President 0
Value: $0
Jan 01, 2026
Buy
Restricted Stock Units
A-Award
Levin Rami
CEO And President
CEO / President 19 000
Value: $99.6K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Gumulka Jerzy
Director
Director 1 517
Value: $18.9K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Downs Christopher
Chief Financial Officer
C-Suite Officer 4 881
Value: $146.4K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Charles Faith L.
Director
Director 1 517
Value: $18.9K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Mahery Amy
Director
Director 1 517
Value: $18.9K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Climaco John M
Chief Executive Officer
CEO / President 9 761
Value: $292.8K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Cockroft Bettina M.
Director
Director 1 517
Value: $18.9K
Nov 17, 2025
Buy
Option to purchase common stock
A-Award
Keyes Jeffry R.
Director
Director 1 517
Value: $18.9K
Jul 30, 2024
Buy
Common Stock
J-Other
Cortice Biosciences, Inc.
Insider
Other 0
Value: $0
Jul 30, 2024
Buy
Common Stock
J-Other
Cortice Biosciences, Inc.
Insider
Other 0
Value: $0
Jul 29, 2024
Buy
Common Stock
Cortice Biosciences, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Jul 29, 2024
Buy
Common Stock
Cortice Biosciences, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Cockroft Bettina M.
Director
Director 17 500
Value: $0
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Climaco John M
Chief Executive Officer
CEO / President 83 000
Value: $21.5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Mahery Amy
Director
Director 17 500
Value: $0
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Mahery Amy
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Keyes Jeffry R.
Director
Director 17 500
Value: $0
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Keyes Jeffry R.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Gumulka Jerzy
Director
Director 17 500
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CNS PHARMACEUTICALS, INC.
CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE